BPC-157 vs LL-37
A side-by-side research comparison of BPC-157 and LL-37 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | BPC-157 | LL-37 |
|---|---|---|
| Full name | Body Protection Compound-157 | Cathelicidin Antimicrobial Peptide LL-37 |
| Category | Healing & Recovery | Healing & Recovery |
| Status | Research compound | Research compound |
| Mechanism | Upregulates growth factor expression including VEGF and promotes angiogenesis, modulates nitric oxide system, and interacts with the dopaminergic system. | Disrupts microbial membranes, neutralizes endotoxins, recruits immune cells via chemotaxis, and promotes angiogenesis and re-epithelialization. |
| Molecular weight | 1419.53 Da | 4493.33 Da |
| Half-life | ~4 hours | ~4-6 hours |
| Bioavailability | Variable; oral and injectable forms available | Variable by route; topical and injectable |
| Typical dose | 250-500 mcg per dose | 50-100 mcg |
| Frequency | 1-2x daily | Daily |
| Route | Subcutaneous injection (or oral capsules) | Topical or subcutaneous injection |
BPC-157 reported benefits
- Accelerated tendon and ligament healing
- Gut lining protection and repair
- Neuroprotective effects
- Anti-inflammatory properties
- Muscle tear recovery
LL-37 reported benefits
- Broad-spectrum antimicrobial
- Wound healing acceleration
- Biofilm disruption
- Immune system enhancement
Related comparisons
Research and educational reference only. Not medical advice.